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Abstract
Transglutaminase activity, arising potentially from transglutaminase 2 (TG2) and Factor XIIIA (FXIIIA), has been linked to
osteoblast differentiation where it is required for type I collagen and fibronectin matrix deposition. In this study we have
used an irreversible TG-inhibitor to ‘block –and-track’ enzyme(s) targeted during osteoblast differentiation. We show that
the irreversible TG-inhibitor is highly potent in inhibiting osteoblast differentiation and mineralization and reduces secretion
of both fibronectin and type I collagen and their release from the cell surface. Tracking of the dansyl probe by Western
blotting and immunofluorescence microscopy demonstrated that the inhibitor targets plasma membrane-associated FXIIIA.
TG2 appears not to contribute to crosslinking activity on the osteoblast surface. Inhibition of FXIIIA with NC9 resulted in
defective secretory vesicle delivery to the plasma membrane which was attributable to a disorganized microtubule network
and decreased microtubule association with the plasma membrane. NC9 inhibition of FXIIIA resulted in destabilization of
microtubules as assessed by cellular Glu-tubulin levels. Furthermore, NC9 blocked modification of Glu-tubulin into 150 kDa
high-molecular weight Glu-tubulin form which was specifically localized to the plasma membrane. FXIIIA enzyme and its
crosslinking activity were colocalized with plasma membrane-associated tubulin, and thus, it appears that FXIIIA crosslinking
activity is directed towards stabilizing the interaction of microtubules with the plasma membrane. Our work provides the
first mechanistic cues as to how transglutaminase activity could affect protein secretion and matrix deposition in
osteoblasts and suggests a novel function for plasma membrane FXIIIA in microtubule dynamics.
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Introduction
Bone is a highly dynamic connective tissue that is remodelled
throughout life by the reciprocal activity of two different bone cell
types – osteoclasts that resorb bone and osteoblasts that form new
bone. Defective osteoblast activity leads to insufficient bone de-
position and contributes to the development of bone degenerative
diseases such as osteoporosis [1,2]. Osteoblasts arise from mesen-
chymaloriginsand lineagedifferentiationisunderthemastercontrol
of Cbfa1 (Runx2) and Osterix transcriptionfactors as well as myriad
of signaling pathways [3–5]. Mature and fully differentiated
osteoblasts deposit bone matrix, of which 90% is collagen type I
(COL I) by weight; the remaining 10% is composed of bone matrix
noncollagenous proteins and small proteoglycans, many still having
unassigned functions [1,6]. The fibrillar COL I matrix, in addition
to being a main structural determinant in bone, also plays a major
role in regulating osteoblast activity and it is known to be required
for expression of osteoblast markers, such as alkaline phosphatase
[7–9], which promotes the removal of inhibitory pyrophosphate
thus promoting mineral deposition – the end stage of bone
formation[10]. COL I synthesis, secretion, assembly and deposition
are regulated by a vast and multilevel cellular machinery that
includes COL I modifying enzymes (such as prolyl-hydroxylases)
that influence COL I stability, COL I folding chaperones, Golgi-to-
plasmamembranetraffickingofCOLI containingsecretoryvesicles
[11–13], propeptidases, and matrix residing factors such as
fibronectin (FN), the latter acting as a provisional scaffold for
COL I deposition and matrix assembly [14,15]. Appropriate,
sequential orchestration of each step is required for elaboration of
permanent COL I matrix receptive to mineralization.
We have recently demonstrated that FN and COL I matrix
deposition by osteoblasts require transglutaminase (TG) enzyme
activity; however, the precise mechanisms of action have remained
largely unknown [16]. TGs are a family (currently comprising nine
proteins; TG1, TG2, TG3, TG4, TG5, TG6, TG7, Factor XIIIA
and inactive erythrocyte TG) of widely distributed enzymes that
catalyze a Ca
2+-dependent acyl-transfer reaction between poly-
peptide-bound glutamine residues and primary amines, resulting
in the formation of a covalent c-(glutamyl)-e-lysyl bond (an
isopeptide crosslink) between substrate proteins [17–20]. This
enzymatic reaction is exclusively performed by TGs and can take
place at the cell surface and/or in extracellular matrix (ECM)
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2+ concentration. The
active site of TG enzymes is highly conserved throughout the
family and across different species and includes a central cysteine
residue [19,20]. TG-reactive glutamine-donor substrates include a
vast array of proteins. Some of them are matricellular cell
adhesion proteins such as laminin, fibronectin, thrombospondin
and osteopontin [21–26]; however, intracellular and cytoskeletal
substrates have been also been identified [27,28]. TGs are thought
to stabilize cell-matrix adhesion and the matrix itself, by fixing and
crosslinking its constituents [18], however, the cellular functions of
many TG substrates still remains obscure. We have demonstrated
that TG-activity affects FN and COL I matrix formation and have
shown that MC3T3-E1 osteoblasts express two TG family
members, transglutaminase 2 (TG2) and Factor XIIIA (FXIIIA),
both of which are also found in bone in vivo [16,29,30]. Both TG2
and FXIIIA have long been linked to formation of skeletal
elements and have been shown expressed during both intramem-
braneous and endochondral ossification [29,31,32]. TG2, which is
the most widely distributed TG enzyme, appears to have a major
function on the cell surface in cell adhesion as a FN-binding, co-
factor for b1-integrin [33–39] and it has been demonstrated that
this function may not implicate its crosslinking activity [37,38,40].
Cell-surface TG2 promotes integrin clustering and potentiates
integrin downstream effects including RhoA activation [41]. TG2
also appears to have a pro-mineralizing effect in chondrocytes and
vascular smooth muscle cells [42,43] and it has been also linked to
chondrocyte hypertrophy [44–49]. FXIIIA – best known as a
blood coagulation cascade transglutaminase [50,51] – is also found
in osteoblasts and in hypertrophic chondrocytes [16,46,49,52].
Indeed, growing evidence indicates that these two enzymes have
similar and/or overlapping, but not necessary identical, functions
in connective tissue cells.
Although it is evident from our previous work that TG activity
regulates osteoblast differentiation and matrix deposition in cell
culture [16], the existing in vivo data from individual TG2 - and
FXIIIA-knockout mice show no immediate bone-related develop-
mental phenotypes [53,54,55]. Hence, no specific roles for either
of these enzymes have been assigned in bone or in cartilage
developmental processes and it has been suggested that TG2 and
FXIIIA have either a synergistic function or functional redundan-
cy, and that they can in some cases compensate for each other
[52,56,57]. Indeed, Tarantino et al. (2009) have recently shown
that the observed normal musculoskeletal phenotype of TG2
knockout mice likely arises from the overexpression of FXIIIA in
these tissues. Furthermore, it has been shown that TG2 is required
for the mobilization of FXIIIA in hypertrophic chondrocytes [49],
again indicating that the two enzymes could be in complementary
pathways. Despite this potential tight functional link between TG2
and FXIIIA, the two enzymes have very different expression levels
and localization patterns in osteoblasts [16]. In osteoblasts TG2
mRNA and protein levels remain constant throughout the dif-
ferentiation program, and TG2 is found in a punctate pattern on
the cell surface [16], which likely represents recycling endosomes
where TG2 is found in fibroblasts and endothelial cells [58].
FXIIIA mRNA and protein expression on the other hand are
dramatically induced by ascorbic acid [16], which is also known to
stimulate the MAP kinase pathway, ERK1/2 signaling and COL I
expression [59]. Furthermore, FXIIIA levels continue to increase
steadily during differentiation and the enzyme appears in
abundance on the cell surface and in the ECM upon ascorbic
acid treatment, indicating that FXIIIA could play a major role in
osteoblast differentiation and COL I matrix formation [16].
In the present study, we have examined the role and mechanism
of action of TG activity during osteoblast differentiation. We
sought first to determine which of the two TGs – TG2 and/or
FXIIIA – contribute to protein crosslinking activity, and second, to
determine where this crosslinking occurs and how it might affect
COL I matrix formation. Since accumulating evidence (as
outlined above) implies that genetic ablation of these two enzymes
can cause compensatory expression of the other enzyme [56] and
hence possibly a misrepresentation of function, we have opted for
a chemical ‘‘block-and-track’’ approach to reveal activity and to
elucidate which enzyme(s) is active during cell differentiation. Our
approach makes use of an irreversible TG inhibitor (NC9) that
mimics the commonly used TG donor substrate analogue, Cbz-
Gln-Gly and bears a dansyl group that allows inhibitor tracking
[60]. In this report, we show that NC9 is highly potent in
inhibiting osteoblast differentiation and mineralization, where it
reacts with and deactivates FXIIIA. TG2 crosslinking activity does
not contribute to osteoblast differentiation. Our work also provides
the first mechanistic cues as to how transglutaminase activity could
affect protein secretion and matrix deposition and suggests a
highly novel function for plasma membrane FXIIIA in microtu-
bule dynamics.
Results
TG activity regulates collagen deposition and
mineralization in osteoblast cultures
To investigate the mechanisms by which TG activity regulates
osteoblast differentiation and COL I deposition, we have used an
irreversible inhibitor to block TG crosslinking activity. This
inhibitor, referred to herein as NC9, bears similarity to previously
developed irreversible inhibitors designed to mimic the commonly
used TG donor substrate Cbz-Gln-Gly [61,62]. Synthetic schemes
are included in the Materials and Methods. As shown in Fig. 1A,
the central peptidic scaffold bears a Cbz group, conferring affinity
for the glutamine substrate binding site. On the amino acid side-
chain it bears an electrophilic acryloyl group that can react with
the active-site Cys thiol, blocking it covalently and irreversibly.
NC9 also bears a dansyl group, attached to the peptidic moiety via
a short PEG spacer, which allows tracking of the site of inhibition
and enzymes that react with the inhibitor.
MC3T3-E1 cell differentiation was induced with AA+bGP
supplementation to the culture media, referred to herein as
differentiation medium (DM). As determined by the MTT cell
viability assay, NC9 was nontoxic to the cells at up to 100 mM
concentration, and it did not affect general cell growth (data not
shown). In the presence of 25 mM NC9, in situ TG reactivity with a
biotin-pentyl amine probe (bPA) was shown to result in markedly
decreased TG-mediated labeling of the cell layers (Fig. 1B).
Fluorescence quantification, that was used to estimate TG-activity
in cultures, showed a reduction down to 51% of the control value
upon NC9 treatment (Fig. 1B). At the highest concentration tested
of 50 mM, NC9 blocked mineralization of the cultures, as
visualized by von Kossa staining, and reduced Ca
2+ accumulation
in cell-matrix layer to 10% of the control level (Fig. 1C,D).
Similarly, COL I deposition, as measured by Picrosirius staining,
was reduced significantly to 20% of controls upon 50 mM NC9
treatment (Fig. 1E). Control compound NC10, which was
designed to be identical to NC9 but without a reactive warhead
side chain had minimal effects on COL I deposition, and was not
incorporated into any cellular proteins (Fig. S1).
TG inhibition blocks COL I secretion and release from the
cell surface
A detailed investigation of cellular COL I production by
immunofluoresence microscopy showed that extracellular COL I
FXIIIA Regulates Microtubule Dynamics
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Fibrils were scant and COL I staining appeared punctate and
discontinuous (Fig. 2A). The residual matrix COL I appeared
bound to the cells as evident by colocalization of COL I with actin
(Fig. 2A). In cells treated with a-MEM medium only, small
amounts of COL I were produced (Fig. 2A). Control cells treated
with differentiation medium alone deposited normal COL I fibrils.
These findings were further supported by Western blot analysis of
subcellular fractions (cytosolic, membrane and cytoskeletal/
matrix) which showed that NC9-treated cells had begun a1(I)
and a2(I) collagen chain production similarly as normal differen-
tiating cells. In both treatments proteins were found in the
cytoskeletal-matrix fraction, although slightly lower levels were
observed upon NC9-treatment (Fig. 2B). Analysis of COL I levels
on the cell surface via biotinylation experiments demonstrated that
the NC9 treated cells had externalized and processed some COL I
into triple helical format, but COL I mostly cell-associated
(individual a-chains at 70 kDa visible under reducing conditions)
(Fig. 2C).
To further analyze levels of COL I secretion and processing, we
detected COL I C-propeptide levels (LF-41 antibody) [63] in the
conditioned medium collected from cells after 2, 4 and 6 days of
culture (Fig. 2D). This analysis demonstrated that differentiating
cells had expected abundant free, cleaved C-terminal propeptide,
but NC9-inhibited cultures had negligible amounts of secreted,
free C-terminal propeptide. Collectively, this demonstrates that
TG-inhibited cells express and translate COL I mRNA into
protein normally, but cannot secrete the protein and/or release
collagen to the matrix; i.e., COL I matrix production was arrested
at an early secretory and matrix assembly stage.
Inhibition of TG affects FN deposition and secretion
We have previously reported that TGs can affect FN matrix
formation, which begins at a very early stage of osteoblast
differentiation process [16]. Also, Mov13 cells which do not
express COL I have defective FN matrix deposition [64].
Therefore, we investigated the effects of NC9 on FN matrix.
Figure 3A shows that NC9 also reduces FN matrix formation.
Closer inspection reveals that cultures treated either with medium
alone or with differentiation medium both assemble FN matrix
(non-differentiating cultures in lower quantity) whereas NC9-
treated cells retain FN at the cell surface (Fig. 3A). Colocalization
of FN with cytoskeletal actin shows that FN is indeed associated
with the cells and no bone fide matrix fibrils are formed (Fig. 3B).
The actin cytoskeleton, which participates in FN assembly, was
normally formed with inhibitor treatment (Fig. 3B). Comparing
Figure 1. Dose-dependent inhibition of mineralization and COL I deposition in MC3T3-E1 osteoblast cultures by the irreversible TG
inhibitor NC9. (A) Structure of NC9. Activity is based on the peptidic scaffold, which provides affinity for the glutamine substrate binding site, and
on an electrophilic acryloyl group on the amino acid side-chain that is attacked by the active site cysteine. The inhibitor is thus attached to active site,
covalently and irreversibly. (B) In situ TG-activity (biotin-pentylamine, bPA, labeling) of the control cultures treated with differentiation medium (DM)
alone and with DM and 25 mM NC9. NC9 treatment reduced TG activity in cultures down to 51% of the control as estimated by fluorescence intensity
quantification using IMAGE-J software (version 1.37a, National Institutes of Health, USA). (C) Inhibition of mineral deposition with NC9. Mineralization
was visualized by von Kossa staining. Complete absence of mineralization was observed in the presence of 25 and 50 mM NC9. (D) Reduction of Ca
2+
deposition in the NC9-treated cultures. Ca
2+ deposition in the cell layers was reduced to 46%, 12% and 9% of control with 10, 25 and 50 mM NC9,
respectively. (E) COL I deposition in the cultures as assessed by Picrosirius staining. COL I levels were reduced down to 61%, 45% and 19% of the
controls with 10, 25 and 50 mM NC9 treatments, respectively. M, medium; DM; differentiation medium (AA+bGP). Error bars represent s.e.m. of two
separate experiments done in triplicate.
doi:10.1371/journal.pone.0015893.g001
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and cytoskeletal/matrix) (Fig. 3C) showed that slightly more FN
was found in the cytoskeleton/matrix fraction in NC9-treated
cultures than in normal cells. This cytoskeletal FN appeared to
have a higher molecular weight than the FN released from the cell
surface of normal cells which could indicate that differentiating
cells are releasing FN from cell surface and incorporating it into
insoluble matrix, but that NC9 treated cells are not. To investigate
the formation of insoluble FN matrix in these cells, we fractionated
the cell layers into deoxycholate-soluble and insoluble fractions
and analyzed the material by non-reducing Western blotting to
visualize FN stabilized via cysteine-bridges. Figure 3D shows that
Figure 2. NC9 treatment reduces COL I deposition and secretion. (A) Immunofluorescence staining of COL I (green) in nonpermeabilized
control (DM) and NC9-treated cultures. Cytoskeletal actin was visualized with phalloidin-568 (orange). COL I was deposited into a fibrillar networki n
differentiating cells (with DM) whereas NC9-treated cells had only discontinuous, punctate COL I in the matrix. (B) Subcellular localization (C, cytosolic,
Me, membrane; Ck/m, cytoskeleton/matrix) of COL I in NC9-treated and control cells. Vimentin was used as loading control for the cytoskeletal/matrix
fraction. Cells treated with NC9 produce COL I although at slightly lower level than differentiating cells. COL I is associated with the cytoskeleton. (C)
Cell surface (CS) bound COL I as analyzed from biotinylated cell surface material. NC9-treated cells process some COL I but retain it on the cell surface.
(D) COL I assembly and secretion into conditioned medium as analyzed by release of collagen C-terminal propeptide from the tropocollagen (by LF-
41 antibody). NC9 treatment reduces COL I secretion and assembly into the matrix.
doi:10.1371/journal.pone.0015893.g002
FXIIIA Regulates Microtubule Dynamics
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e15893Figure 3. TG inhibition by NC9 reduces FN matrix deposition and secretion by the cells. (A) Immunofluorescence staining of FN matrix
(green) in nonpermeabilized control (DM) and NC9-treated cultures. FN matrix assembly was dramatically reduced and FN appeared attached to the
cells. Upper panels represent low-magnification images and lower panels are high-magnification images of the boxed areas above. (B) Colocalization
of FN (green) and actin cytoskeleton visualized with phalloidin-568 (orange) demonstrating the cellular attachment of FN in NC9-treated cells. No
bone fide FN fibrils were observed as in control cells. (C) Effect of NC9 on subcellular localization (C, cytosolic, Me, membrane; Ck/m, cytoskeleton/
matrix) of FN in NC9 and control cells as analyzed by Western blotting. All cellular FN was found in cytoskeletal fractions in all treatments. Vimentin
was used as loading control of the cytoskeletal fraction. Normal, differentiating (with DM) cells appeared to have less high-molecular weight FN (hmw
FN) suggesting that this processing precedes release of FN to the matrix. (D) Formation of deoxycholate (DOC) soluble and insoluble FN matrix
analyzed by nonreducing Western blots. NC9-treatment did not affect the soluble FN matrix, but reduced the formation of DOC-insoluble matrix. (E)
FN secretion to conditioned medium (CM) was reduced at day 6 upon NC9 treatment as analyzed by Western blotting.
doi:10.1371/journal.pone.0015893.g003
FXIIIA Regulates Microtubule Dynamics
PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15893whereas deoxycholate-soluble FN was not changed in differenti-
ating and NC9-treated cells, FN levels in the insoluble fraction
were slightly decreased upon NC9 treatment. Secreted FN levels
remained similar in all treatments, up to day 4, however, at day 6,
inhibitor treatment caused cells to secrete markedly less FN
compared to the control cells (Fig. 3E). These results further
confirm that TG inhibitor NC9 treated cells are arrested at a very
early stage of matrix deposition and/or secretion.
FXIIIA is the main crosslinking transglutaminase
orchestrating matrix assembly
To elucidate the mechanism whereby TGs regulate matrix
secretion and deposition, we began by examining which enzyme(s)
– TG2 and/or FXIIIA – were able to react with the inhibitor and
in which cellular structures inhibition occurred. Inhibitor visual-
ization was achieved by Western blotting and immunofluoresence
microscopy using an anti-dansyl antibody to detect the dansyl
group of NC9. For identification of the labeled enzyme(s), a new
mouse anti-FXIIIA antibody against a region spanning residues
675–688 of mouse FXIIIA was developed. This antibody did not
detect FXIIIA in nondifferentiating MC3T3-E1 cells at day 6
(medium only treatment) when FXIIIA mRNA was expressed at
very low levels, but detected FXIIIA at day 6 when mRNA had
also been induced by DM (see Fig. S2A,B). Similar results were
seen with a commercial FXIIIA antibody [16]. Furthermore, this
antibody detects full-length FXIIIA in wild type osteoblast
extracts, but not in control extracts of FXIIIA-deficient osteoblasts
(see Fig. S2C).
Western blot analysis of control and NC9-treated cultures
(Fig. 4A) at time points from 6 h to 6 days after induction of
differentiation demonstrated that NC9 is incorporated into one
major protein in the cells at ,70 kDa and was detectable from
12 h onwards – total protein levels remained the same during the
entire time course. No labeling was observed in cultures that were
not treated with the inhibitor, and no labeling was detected as
early as 6 h. Analysis of subcellular fractions showed that NC9 was
localized and found mostly in the membrane fraction (Fig. 4B) and
that the labeling increased from day 2 to day 6. Since total NC9
labeling appeared not to change (Fig. 4A), it is possible that this
represents accumulation of NC9-labelled enzyme on the cell
membrane. The observation that NC9 was found in a membrane
fraction prompted us to investigate whether NC9 had reacted with
FXIIIA or TG2 on the cell surface. For this, we isolated the cell
surface proteins via biotin labeling of cells grown with differen-
tiation medium in the presence or absence of NC9. The
biotinylation method employed involves a certain level of
permeabilization that occurs when the cells are incubated at
4uC; therefore, biotinylation can include also some proteins that
are within the plasma membrane [65,66]. Biotinylated material
was detected by dansyl, FXIIIA and TG2 antibodies. As shown in
Figure 4C, at the cell surface material the band corresponding to
NC9-labeled protein comigrates with FXIIIA band. TG2 was
highly abundant on the cell surface in both treatments but only
found as a high-molecular weight form. Since no NC9 was
detected in high molecular weight material, it is likely that TG2
was not labeled by NC9. This indicates that cell surface TG2 is not
reactive toward NC9 and therefore is inactive and incapable of
mediating crosslinking. Since NC9 was found to be incorporated
into the cells only from 12 h on, we tested if FXIIIA protein
expression was induced between 6 h and 12 h. Immunofluore-
sence images in Fig. 4D show that at the 6 h time point, cells do
not produce FXIIIA but that the protein is present at the 12 h
time point. Western blot analysis (Fig. 4D) also shows weak
induction of FXIIIA at 12 h time point.
For immunofluorescence microscopy detection of cellular
enzymes labeled by NC9, both Triton X-100-permeabilized and
nonpermeabilized cells were used to visualize intracellular and cell
surface/extracellular dansyl-labeling, respectively. Figure S3
shows that permeabilization allows visualization of cytosolic
protein, GAPDH, and nucleus with DAPI and omission of this
step blocks cytosolic GAPDH staining but not the staining of
nucleus. Detection of permeabilized cells with an anti-dansyl
antibody (Fig. 5) showed significant intracellular NC9 labeling that
was completely colocalized with FXIIIA, but not with TG2, the
latter thought to be inactive and in a closed conformation in the
intracellular space at low Ca
2+ concentration [67]. Since the
cytoplasmic extract did not have any covalently incorporated
NC9, the intracellular colocalization between FXIIIA and NC9
indicates that the inhibitor interacts with the enzyme, but no
crosslinking/catalysis occurs, i.e., FXIIIA enzyme is likely inactive
inside the cell. Nonpermeabilized cells showed similar complete
colocalization with NC9 and FXIIIA (Fig. 5B), confirming our
Western blot results (vide supra); i.e., that the cell surface and
plasma membrane associated FXIIIA enzyme reacts with NC9. In
Fig. 5B TG2 shows some colocalization with NC9; however, since
we had confirmed by immunoblotting that TG2 was not labeled
by NC9, we hypothesize that the observed partial TG2 and NC9
colocalization derives from TG2 and FXIIIA colocalization on the
cell surface. Close examination of nonpermeabilized cells with a
higher resolution microscope clearly shows that TG2 and FXIIIA
are co-localized and associated on the cell surface (Fig. 5C). TG2 is
found in small 1 mm-sized rounded structures that could represent
TG2 in endo/exosomes and TG2 clusters with b1-integrin as
reported before in endothelial cells [41,58]. FXIIIA was found to
be localized mostly in larger, 5 to 7 mm-diameter rounded patches.
TG2 co-localized with FXIIIA in these areas as shown at higher
magnification (Fig. 5C, insets). The disappearance of NC9-
containing patches with permeabilization using a detergent
indicates that they are very sensitive to any changes in plasma
membrane integrity and that FXIIIA could be somewhat weakly
associated with the plasma membrane.
NC9 destabilizes microtubules and decreases plasma
membrane microtubule levels
Based on all the results above, we hypothesized that FXIIIA
crosslinking activity could be part of the secretory machinery and
involved in assisting secretory vesicles transport to the plasma
membrane to promote matrix protein secretion. Secretory vesicles
are transported from the Golgi apparatus to the plasma membrane
by motor proteins which move along microtubules (MTs) towards
the cell surface where they dock to the cell membrane, fuse and
release their contents to the cell surface or to the matrix
[12,68,69]. The role of MTs in COL I secretion is well established
[70]. Hence, we hypothesized that cell surface and plasma
membrane associated FXIIIA could regulate secretion by affecting
stabilization of MTs and/or assisting MT attachment to the cell
cortex and/plasma membrane. Furthermore, MT destabilization
has been shown to increase FN interaction with cells, i.e., this
being possible explanation why NC9 could also block release of
both FN and COL I to the matrix [71].
To gain evidence for this, we examined if the MT network is
altered in cells that were treated with NC9. Fig. 6A shows that
intracellular tubulin levels (in permeabilized cells) initially appear
unchanged in both control and NC9-treated cells. However, closer
inspection of the MT network, depicted in a high contrast black
and white immunofluorescence image (Fig. 6B) shows that control
cells have MTs that are directed towards the cell surface, whereas
NC9-treated cells show more cage-like MTs whose appearance in
FXIIIA Regulates Microtubule Dynamics
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cell cortex [72]. Examination of nonpermeabilized cells (Fig. 6A,
lower panels) showed that in control experiment, normal
differentiating cells have clusters of plasma membrane-associated
tubulin, whereas in NC9-treated cells, the plasma membrane-
associated tubulin was spread along the plasma membrane.
Medium only treated cells, which do not have FXIIIA on cell
surface, also formed these plasma membrane tubulin patches
indicating that FXIIIA is not required for their formation, but
likely needed for their maintanace during COL I secretion (Fig.
S4). Adding NC9 to medium only treated cells that do not produce
FXIIIA, had no effect on tubulin patches (Fig. S4). To gain more
evidence that in NC9-treated cultures MTs could be destabilized
and/or not associated with the plasma membrane, we examined
Figure 4. NC9 incorporates into membrane and cell surface-associated FXIIIA. (A) Western blot analysis of NC9 incorporation into
osteoblast proteins. Cells were grown in the presence or absence of NC9 from 6 h to 6 days and proteins were extracted and immunoblotted using
anti-dansyl antibody. NC9 was incorporated into one protein at 70 kDa from 12 h onwards and levels of labeling remained similar at all time points.
No labeling was observed in control cultures (DM) not incubated with NC9. b-Actin was used as loading control. (B) Subcellular localization of dansyl-
group revealed that NC9 had labeled FXIIIA in the membrane fraction (Me) and this labeling increased from day 2 to day 6. Pan-cadherin (pan-cad)
was used as loading control. (C) Western blot analysis of biotinylated cell surface proteins from NC9-inhibited cultures. NC9, detected by dansyl
antibody comigrated with FXIIIA at 70 kDa. Cell surface TG2, which is found in high-molecular weight complexes ($250 kDa), was not labeled by
NC9, indicating that TG2 is not mediating crosslinking during differentiation. (D) Induction of FXIIIA protein expression after 12 h of differentiating
treatment (DM) analyzed by immunofluoresence staining of nonpermeabilized cells.
doi:10.1371/journal.pone.0015893.g004
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PLoS ONE | www.plosone.org 7 January 2011 | Volume 6 | Issue 1 | e15893Figure 5. Immunofluorescence colocalization of NC9 with FXIIIA and TG2. (A) Intracellular immunofluoresence colocalization (yellow) of
NC9 with FXIIIA and TG2 (both green) shows complete colocalization of the inhibitor with FXIIIA, but no colocalization with TG2. The dansyl group of
NC9 was stained with an anti-dansyl antibody followed by anti-rabbit Alexafluor 568 conjugate (orange). (B) Extracellular colocalization
(nonpermeabilized cells) of NC9 with FXIIIA and TG2 shows complete colocalization (yellow) of the inhibitor with FXIIIA and limited colocalization
with TG2 in a patch-type staining pattern. (C) Colocalization of FXIIIA with TG2 (yellow) showed that these two enzymes are found together on the
cell surface – FXIIIA in larger patches and TG2 in small vesicles.
doi:10.1371/journal.pone.0015893.g005
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tubulin in subcellular fractions by Western blotting. MTs are
stabilized by a detyrosinylation step which exposes Glu-residues in
the C-terminus of tubulin such that Glu-tubulin is a marker for
MT stability. Fig. 6C shows that in osteoblasts, Glu-tubulin is
found in two forms in differentiating and NC9 treated cells - as a
50-kDa monomer and as a 150-kDa form that may represent a
Glu-tubulin complex with itself or with another protein. Medium
only treated cells, which do not express FXIIIA protein, had only
50 kDa Glu-tubulin (Fig. 6C). NC9 treatment reduced total Glu-
tubulin levels (in all cellular fractions added together) to 44% of
control, differentiating cells as evaluated after normalization of a-
tubulin and Tyr-tubulin. This indicates that FXIIIA is directly or
indirectly involved in generation of total Glu-tubulin. Furthermore,
Figure 6. FXIIIA inhibition by NC9 affects microtubule dynamics. (A) Immunofluorescence staining of tubulin (green) and DAPI (blue) in
permeabilized and nonpermeabilized cells. Staining under these conditions shows intracellular (IC) tubulin (permeabilized cells) and plasma
membrane associated (PM) tubulin (a-tub) (green). Marked difference were found in the distribution of tubulin in the nonpermeabilized cells where
tubulin was found in rounded patches in normal cells (DM), but spread along the plasma membrane in NC9-treated cells. (B) High-magnification
images of microtubule networks after processing into high-contrast black and white images. FXIIIA inhibited, NC9-treated cells had a more cage-like
microtubule network, whereas in control cells microtubules pointed towards the cell surface. (C) Western blot analysis of the levels and subcellular
distribution of Glu-tubulin (detyrosinylated and stabilized tubulin) showing that NC9-treated cells have less Glu-tubulin compared to control cells.
Glu-tubulin was found in two forms in differentiating cells (DM), as 50 kDa monomer in cytosolic fraction and 150 kDa high molecular weight form
which was found in the membrane preparation. Tyr-tubulin and a-tubulin levels were similar with DM and DM+NC9 treatments. Medium only treated
cells (M) did not show any 150 kDa Glu-tubulin. (D) Ratio of 150-kDa vs 50-kDa Glu-tubulin in control and NC9-treated cells showing that NC9
decreases the levels of membrane-associated 150-kDa Glu-tubulin and increases the cytosolic 50-kDa Glu-tubulin in the cells. The levels were
quantified using Quantity One software and two Glu-tubulin forms are presented as % of total Glu-tubulin and are normalized to a-tubulin levels.
doi:10.1371/journal.pone.0015893.g006
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the150-kDa Glu-tubulinandmore ofthe50-kDa tubulincompared
to the control (Fig. 6D) suggesting that changes are occurring as a
result of NC9 inhibition of FXIIIA and that that FXIIIA could be
involved directly or indirectly in generating these complexes.
Moreover, the 150-kDa Glu-tubulin was found mostly in membrane
fraction, whereas the 50-kDa Glu-tubulin was mostly located in
cytosol, indicatingthat the 150-kDa Glu-tubulin could be associated
with the plasma membrane. Tyr-tubulin detection in the same
samples showed no changes upon NC9 treatment and it is possible
that the Glu-tubulin vs. Tyr-tubulin ratio is so low that minor
changes in total Tyr-tubulin levels are simply not observed. Similar
observations have been made by others [73]. Interestingly, both
Tyr-tubulin and a-tubulin were present in membrane fraction
indicating that tubulin can associate with plasma membrane.
To determine whether FXIIIA and NC9 could regulate the
delivery of secretory vesicles to the cell surface, we investigated the
levels of synaptotagmin VII (Syt VII), a secretory vesicle marker on
the cell surface. Syt VII was recently demonstrated to be critical
for osteoblast function and matrix deposition in vivo [74]. Syt VII is
involved in docking and fusion of vesicles with the plasma
membrane where it participates in formation of the SNARE
complex [75]. Synaptotagmin becomes part of the cell membrane
during successful exocytosis and portions of the protein protrude
the plasma membrane and are detectable on the cell surface of
secretory cells from the matrix side [76]. Figure 7A and B shows
that Syt VII levels on the plasma membrane and cell surface are
significantly lower in NC9 treated cells and decreased down to
29% of controls as measured by immunofluoresence quantification
(Fig. 7B). Furthermore, in control cells Syt VII is colocalized with
plasma membrane tubulin in patches on the cell surface, whereas
in NC9 treated cells have none of this colocalization (Fig. 7A).
These results confirm that secretory process is defective and linked
to defective microtubule association with plasma membrane.
These results also indicate that the observed tubulin patches are
linked to the secretory process.
Finally, we examined if FXIIIA and the site of its activity are
colocalized with tubulin on the cell surface of normally
differentiating cells. Fig. 8A shows that, FXIIIA is found
colocalized with plasma membrane-associated tubulin in 5 to 7-
mm patches. Enzyme activity and presence of crosslinking was
assessed by growing the cells with Q-substrate probe monodansyl
cadaverine (MDC), a fluorescent primary amine that mimics a
lysine residue in crosslinking reaction and is incorporated into TG-
reactive Q-residues in specific proteins that serve as substrates for
TGs. We have previously demonstrated that FN is the main Q-
donor substrate in osteoblast matrix and accumulates in large
quantities in the cells [16], however, many other cellular substrates
may exist [27,28]. As demonstrated in Fig. 8B, immunofluoresence
staining shows clear MDC incorporation into the patches and
colocalization with tubulin indicating that it could be crosslinked
by FXIIIA at these sites.
Discussion
TG-mediated protein crosslinking has long been associated with
matrix formation in physiological events such as bone formation,
but also in pathological circumstances such as fibrosis where
activity has been mostly linked to TG2 [77,78]. In this study, we
show that during osteoblast differentiation and COL I and FN
matrix formation TG2 is inactive and crosslinking activity arises
from plasma membrane-associated FXIIIA. Inhibition of FXIIIA
results in a disorganized MT network, destabilization of MTs and
lower levels of clustered plasma membrane-associated tubulin, as
well as decreased secretory vesicle delivery to the plasma
membrane indicating that FXIIIA crosslinking activity is directed
to stabilize the interaction of MTs with plasma membrane (Fig. 9).
Since MT association with plasma membrane is required for the
promotion of secretory vesicle (exosome) trafficking and protein
delivery to cell surface and secretion to the matrix, our work
suggests a mechanism by which FXIIIA can regulate matrix
deposition and proposes a novel function for cellular and plasma
membrane FXIIIA in MT dynamics.
Although FXIIIA is best known for its role in blood coagulation,
where it is present as a pro-enzyme dimer bound to dimeric
inhibitory FXIIIB subunits (A2B2) and where it stabilizes fibrin
clots after thrombin activation [50,51], growing evidence points to
additional cellular roles. FXIIIA is expressed by several cell types,
including platelets, monocyte-macrophage lineage as well as
fibroblasts, chondrocytes and osteoblasts [50,52,80] where it has
been linked to COL I biosynthesis and deposition in fibroblasts
and osteoblasts [16,81]. The role of cellular FXIIIA in COL I
Figure 7. FXIIIA inhibition by NC9 reduces the levels of Synaptotagmin VII, secretory vesicle marker, on the plasma membrane. (A)
Immunofluorescence staining of the secretory vesicle marker synaptotagmin VII (Syt VII) and it’s colocalization with plasma membrane tubulin in
control (DM) and NC9-treated cells. NC9 treatment markedly lowers Syt VII levels and colocalization with tubulin on the plasma membrane. (B) Syt VII
levels are significantly lower on the cell surface of NC9-treated cells and decreased down to 29% of controls. Levels were quantified by IMAGE-J
software (version 1.37a, National Institutes of Health, USA). Error bars represent s.e.m. of intensity otained from three separate areas in the images.
doi:10.1371/journal.pone.0015893.g007
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that showed decreased COL I production during remodeling and
healing after induced myocardial infarction. In these mice COL I
levels were not corrected by exogenously administered plasma
FXIIIA therapy, indicating that COL I matrix synthesis is
regulated by cellular FXIIIA [82]. FXIIIA is also involved in
tissue repair and FXIIIA deficiency in humans causes delayed
wound closure and healing [83]. Similarly, FXIIIA2/2 mice
exhibit decreased wound closure and re-epithelization; however,
these effects can be corrected by plasma FXIIIA therapy,
indicating that wound healing is orchestrated by extracellular
FXIIIA [84].
Cellular FXIIIA has been described in cytosol and plasma
membrane [80]. Our study demonstrates here that the majority of
cellular FXIIIA crosslinking activity in osteoblasts is associated
with the plasma membrane, where FXIIIA and its activity are
colocalized with tubulin. Plasma membrane-associated FXIIIA
has been described, prior to our work, particularly in macrophage-
lineage cells [57,80,85] where it is colocalized with podosome-like
structures and membrane ruffles of migrating cells [57]. Linder
and coworkers have described that formation of actin-containing
podosomal adhesions is dependent on intact MT network and that
MTs are linked to these adhesion structures at macrophage cell
cortex [86]. Hence it is possible that FXIIIA could regulate MT
dynamics also in macrophages. How FXIIIA associates with the
membrane is currently unknown. The observation that NC9-
FXIIIA staining disappears upon Triton X-100 permeabilization
could indicate that it is weakly associated with outer leaflet of the
plasma membrane. Since FXIIIA does not have transmembrane
domains, nor a signal peptide that could guide its translocation to
the ER-Golgi for modifications such as GPI-anchor insertion, it
remains unknown how this protein could be trafficked and inserted
to its location. The observation that plasma membrane–associated
FXIIIA migrates at ,70 kDa could indicate that it is either
truncated by a protease or modified which could cause different
migration. We know from our previous work that these osteoblasts
do not generate any FXIIIA splice variants [30]. Also, the precise
interaction mechanism between FXIIIA and MTs at the plasma
membrane is not clear; however, many reports are available
describing plasma membrane-associated tubulin and even cell
surface tubulin [87]. Tubulin has been shown to have palmitoyla-
tion for membrane insertion in some cell types and it has been
demonstrated to be present in lipid rafts and interacting with GM1
and GM3 gangliosides [88].
MTs are an integral part of cellular function and regulate
various events from cell motility, to cell shape, to transport and
differentiation [79,89,90]. MTs are comprised of heterodimeric a-
and b-tubulin units that polymerize in a GTP-powered process.
MTs emanate from the microtubule organizing center at the
centrosome and they grow and shrink in a highly dynamic and
rapid polymerization-depolymerization process. MTs are stabi-
lized and protected from depolymerization during various cellular
processes including secretion and differentiation [87,90] and this
occurs initially via detyrosinylation that reveals Glu-residues in
Figure 8. FXIIIA protein and enzyme activity co-localizes with plasma membrane associated tubulin. (A) Immunofluoresence
colocalization (yellow) of FXIIIA (orange) and a-tubulin (green) in normal differentiating (DM) osteoblasts. Colocalization (white arrows) is found in
rounded patches. (B) In situ FXIIIA crosslinking activity is revealed by growing the cells in the presence of Q-probe monodansyl cadaverine (MDC)
which incorporates into transglutaminase reactive Q-residues in substrate proteins in the presence of a transglutaminase activity. Dansyl-probe was
detected using anti-dansyl antibody (orange) and was found in rounded 5 to 7-mm patches and co-localized (in yellow) with plasma membrane a-
tubulin (PM a-tub) (green).
doi:10.1371/journal.pone.0015893.g008
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associated proteins (MAPs) and tau which bind along the MTs to
decrease depolymerization. MT capture to cell cortex occurs via
putative cortical receptors, bridging proteins and MT plus end
binding proteins (+TIPs) such as end binding protein-1 (EB1),
CLIP170 and CLASP [79,87,91]. In our work, we show that in
differentiating osteoblasts, Glu-tubulin is present as a 150-kDa
membrane-associated form whose levels and membrane associa-
tion decrease upon NC9-mediated inhibition of FXIIIA. To our
knowledge, this higher molecular weight Glu-tubulin form, which
could represent a covalent trimeric tubulin complex or a tubulin
complex formed with another protein or proteins, has not been
described before in mammalian living cellular systems. NC9 also
reduces tubulin ‘clustering’ into patches on the plasma membrane
and the fact that FXIIIA and it’s crosslinking activity is found at
sites where tubulin is associated with plasma membrane provides
further evidence that such, covalent stabilization, indeed, occurs.
Covalent tubulin crosslinking by TGs has been demonstrated
before [92,93] and, interestingly, incubation of monomeric tubulin
with TG2 results in high molecular weight tubulin polymers in of
150–160 kDa – similar to what we observe in osteoblasts for Glu-
tubulin [94]. The role of this 150 kDa Glu-tubulin can be only
speculated at this point, but it may represent an additional
stabilization step that could be required for the typical massive and
directed COL I secretory process that occurs during in vitro bone
formation where MTs may need to be ‘locked’ into place at
plasma membrane transiently. This ‘locking’ could to provide long
term MT stability to allow abundant secretory vesicle trafficking to
the plasma membrane via the MT tracks.
In this paper we also describe decreased FN matrix levels upon
FXIIIA inhibition by NC9 which could derive from the decreased
COL I levels in the cells and/or destabilized MTs [71]. Indeed,
our FN staining bears a striking resemblance to FN staining in
Mov13 cells which do not produce COL I. In Mov13 cells, most
FN is retained on the cell surface [64]. It is not known how COL
I regulates FN deposition. Zhang and coworkers [71] have
described that destabilizing MTs in fibroblasts by nocodazole or
vinblastine increases FN binding (70-kDa fragment) to cell layers
and FN assembly on the cell surface. The authors concluded that
MT disruption could modulates FN assembly sites and that
speculated that the event could be linked to cellular contraction
and low cellular GTPase and RhoA levels [71]. The authors also
showed that MT stabilization by taxol abolishes FN binding to
cells, which could represent promotion of FN release from the cell
surface. In other words, MT stabilization could a) promote FN
release from cell surface to promote fibrillogenesis, and b) promote
COL I secretion and further deposition onto FN fibrils.
Although this study focuses on cellular FXIIIA, we have also
published that osteoblasts secrete FXIIIA to matrix and we have
further shown that the extracellular FXIIIA activity steadily
increases during osteoblast differentiation [16]. Although, we are
not addressing the role of secreted FXIIIA in this study, we have
shown before that FN in the matrix acts as a major TG substrate
during osteoblast differentiation and that it co-localizes with COL
I in the matrix suggesting interaction or covalent crosslinking.
Hence, it is yet possible that FXIIIA has a further role in
stabilizing COL I-FN matrix. TG2 in MC3T3-E1 osteoblasts
appears not to be secreted as a full length protein, but as a cleaved
fragment which has increased ATPase activity and no crosslinking
activity [95,96]. Therefore, it would be unlikely that TG2 would
participate in matrix stabilization. Whether TG2 could influence
earlier osteoblast differentiation stages, upstream of FXIIIA func-
tion, via its GTPase acivity and/or its role in mediating integrin-
FN interaction is currently under investigation. We show in this
study that TG2 and FXIIIA are colocalized on the osteoblast
surface and links between the functions of the two enzymes are
supported by our new findings presented in this paper and recent
reports. These include studies from the Belkin group, who have
shown that cell surface TG2 binds non-enzymatically to FN and
promotes integrin clustering and activates RhoA [41], and studies
that show how MTs interact with early focal adhesions and how
focal adhesion kinase and RhoA increase MT stability and the
levels of Glu-tubulin in fibroblasts attached to FN [73,97]. This
suggests that stable adhesion is required to promote MT sta-
bilization. Hence, the potential synergy between TG2 and FXIIIA
could be in the interplay between adhesion and MT network and
further stabilization of adhesion via matrix synthesis and assembly.
Materials and Methods
Synthesis
The Cbz-protected lysine, and coupling reagents were purchased
from GL Biochem; Wang resin was purchased from NovaBiochem.
All other reagents were obtained from Sigma-Aldrich. Reactions
requiring anhydrous conditions were carried out under a dry
nitrogen atmosphere employing conventional benchtop techniques.
1H- and
13C-NMR spectra were recorded on AMXR400 and
AMX300 spectrometers and were referenced to the residual pro-
ton or
13C signal of the solvent. Mass spectra were determined by
FAB+ ionisationon an AutoSpec Q spectrometer. Reactor tubes for
Figure 9. Proposed mechanism whereby FXIIIA crosslinking
activity could affect microtubule dynamics and matrix secre-
tion. Microtubules (MTs) are stabilized via a detyrosinylation step and
captured to the cell cortex via bridging proteins. Secretory vesicles (SV)
are transported along microtubules towards the cell surface where they
dock to, and fuse with, the plasma membrane (PM), releasing their
cargo to the cell surface or to the extracellular matrix. Plasma mem-
brane associated FXIIIA and it’s crosslinking activity may promote the
interaction of MTs with plasma membrane which may involve cross-
linking of Glu-tubulin to itself to another unidentified bridging
protein(s). Precise site of FXIIIA-Glu-tubulin interaction at the cell
periphery is unknown.
doi:10.1371/journal.pone.0015893.g009
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resins were swelled in dimethylformamide (DMF) and washing
steps were performed using CH2Cl2 (DCM) and DMF (EMD
Chemicals). Purification of all peptides was performed using a
preparative HPLC method. Mass spectral data (MS, LCMS) were
all obtained using two different columns: column A: Gemini
C18, 15064.6 mm, 5 m (Phenomenex, Torrance, CA); column B:
Synergi Polar-RP, 15064.6 mm, 4 m (Phenomenex, Torrance,
CA). Crude peptides were purified using a preparative Synergi
Polar-RP, 100621.20 mm (Phenomenex, Torrance, CA) on a




This compound was prepared following our previously
published procedure (Keillor, et al. 2008) and spectral data





eN-Boc-protected amino acid 1
(5.5 mmol) was coupled to Wang resin (1.1 mmol) using DIC
(5.5 mmol) and DMAP (0.11 mmol) (Figure 10). The remaining
free resin hydroxyl groups were capped by treating the resin with a
mixture of acetic anhydride/pyridine (2:3) and shaking for 2 h.
After washing with DMF (3 times with 10 resin volumes) and
DCM (3 times with 10 resin volume), the Boc group was removed
as follows: To the reactor containing 1 g of the Wang resin
supported Cbz-Boc-lysine (2), were added 30 mL of deprotection
mixture, freshly prepared from 470 mL TEA (2 eq.), 1.09 mL of
TMSOTf (0.2 M) and 28.44 ml of anhydrous DCE. The resin was
shaken for 10 min then filtered and washed with 565m Lo f
DCM, 265 mL of DIEA 10% in DCM, 365 mL of DCE.
Deprotection was carried out for another 10 min with a fresh
deprotection mixture. The resin was filtered then washed with
DCM, DIEA DMF and Et2O. Boc removal was verified by
Figure 10. Solid-supported synthesis of synthetic intermediate 5.
doi:10.1371/journal.pone.0015893.g010
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supported Cbz-lysine 3 (1 g) swollen in anhydrous DCM (5 resin
volumes) was added acryloyl acid (2.5 eq.) and EEDQ (2.5 eq.).
The reaction was shaken for 1 hour, followed by washing with
DMF, DCM and ether. The amino acid derivative 4 (Figure 10)
was cleaved from the resin (1 g) by incubating with TFA:DCM
(1:1) for 2 hours. The resulting solution was evaporated and
cyclohexane was added twice and re-evaporated. A minimal
quantity of acetone was added and compound 5 (Figure 10) was
precipitated using diethyl ether with a yield of 67%.
1H NMR (300 MHz, CDCl3) d 7.25 (m, 5H), 6.97 (d, 1H,
J=18 Hz), 6.8 (bs, 1H), 6.13 (m, 2H), 5.53 (d, 1H, J=12 Hz), 5.1
(m, 2H), 4.25 (s, 1H), 3.18 (m, 2H), 1.79 (m, 1H), 1.68 (m, 1H),
1.44 (m, 2H), 1.3 (m, 2H).
13C NMR (75 MHz, CDCl3) d 174.5, 166.5, 156.3, 135.8,
130.6, 128.2, 127.9, 127.0, 165.9, 54.0, 39.5, 31.9, 28.1, 22.5.




In a 100-mL round-bottomed flask, dansyl chloride (0.500 g,
1.9 mmol) was added to 30 ml of DCM, along with NEt3
(0.26 mL, 1.9 mmol). 1,2-Bis(2-aminoethoxyethane) (2.7 mL,
19 mmol) was added dropwise and the reaction was stirred
overnight. Saturated sodium bicarbonate was added to the
reaction mixture and the aqueous layer was washed with
dichloromethane. The aqueous layer was then acidified and
extracted with ethyl acetate. The organic layer was washed with
brine, dried over MgSO4, filtered and evaporated under reduced
pressure to yield a light green oil in 95% isolated yield.
1H NMR (300 MHz, CDCl3) d 8.52 (d, 1H, J=8.4 Hz), 8.35
(d, 1H, J=8.7 Hz), 8.23 (d, 1H, J=7.2 Hz), 7.53 (m, 2H), 7.17 (d,
1H, J=7.5 Hz), 3.51 (m, 4H), 3.44 (m, 4H), 3.10 (t, 4H,
J=4.8 Hz), 2.88 (s, 6H).
13C NMR (75 MHz, CDCl3) d 152.7, 136.1, 131.0, 130.7,
130.5, 130.0, 129.0, 124.0, 119.9, 116.0, 73.3, 71.1, 70.6, 70.3,
46.3, 43.9, 42.2






5 (0.665 g, 1.99 mmol) and 6 (0.910 g, 2.39 mmol) (Figure 11)
were combined with HOBt (0.32 g, 2.39 mmol), EDC (0.46 g,
2.39 mmol) and triethylamine (0.3 mL, 2.39 mmol) in a 25-mL
round-bottomed flask containing 5 ml of DMF. The reaction
mixture was stirred overnight and then poured into 50 mL of
H2O. An extraction was performed whereby the aqueous phase
was washed with dichloromethane and the combined organic
phase was then subsequently washed with 1 M HCl, 1 M NaOH
and a brine solution. The organic layer was then dried over
MgSO4, filtered and the solvent evaporated under reduced
pressure. The residue was purified by flash chromatography
(96:4 DCM:MeOH) to give the pure product as a greenish-yellow
solid in 20% isolated yield.
1H NMR (300 MHz, CDCl3) d 8.52 (d, 1H, J=8.5 Hz), 8.29
(d, 1H, J=8.6 Hz), 8.20 (d, 1H, J=6.7 Hz), 7.48 (m, 2H), 7.27
(m, 5H), 7.15 (d, 1H, J=7.5 Hz), 6.95 (m, 1H), 6.19 (m, 2H), 6.02
(m, 1H), 5.78 (d, 1H, J=7.8 Hz), 5.46 (d, 1H, J=9.9 Hz), 5.05
(m, 1H), 5.04 (s, 2H), 4.17 (m, 1H), 3.43 (m, 10H), 3.21 (m, 2H),
3.04 (m, 2H), 2.86 (s, 6H), 1.72 (m, 2H), 1.46 (m, 2H), 1.36 (m,
2H).
13C NMR (75 MHz, CDCl3) d 165.4, 161.8, 150.5, 132.1,
131.5, 126.4, 126.0, 125.3, 124.8, 123.8, 123.4, 123.1, 122.3,
121.9, 121.4, 117.5, 115.1, 110.5, 70.2, 69.9, 69.5, 69.3, 67.0,
66.1, 48.5, 44.9, 41.9, 34.7, 33.1, 30.5, 26.9, 26.4, 19.2.
HRMS (ESI) calcd for C35H48N5O8S ([M+H]
+): 698.3218,
found 698.3218.
Figure 11. Synthesis of dansyl-labeled probe NC9.
doi:10.1371/journal.pone.0015893.g011
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MC3T3-E1 pre-osteoblast cells (subclone 14) (a generous gift
from Dr. Renny T. Franceschi from the University of Michigan,
School of Dentistry) [98] were plated at an initial density of 50,000
cells/cm
2 for all experiments, except for immunofluorescence
microscopy (IFM) where the initial density was 25,000 cells/cm
2.
Cells were grown in minimal essential medium (MEM) containing
Earl’s salts and nonessential amino acids (Invitrogen; Carlsbad,
CA). Medium was supplemented with 10% fetal Bovine Serum
(FBS) (PAA Laboratories Inc; Canada), 1% Penicillin-Streptomy-
cin (Invitrogen), 1% L-Glutamine (Invitrogen), and 0.225 mM L-
Aspartic acid (Sigma). Cells were grown in a humidified
atmosphere in 5% CO2. Osteoblast differentiation was initiated
24 hours after plating by supplementing the culture medium with
50 mg/ml ascorbic acid and 10 mM b-glycerophosphate as
previously described [9,16]. This medium is referred to hereafter
as differentiation medium (DM). Medium was changed every
second day and experimental end points varied from 6 h to 12
days as stated in the text. TG activity was inhibited by using the
irreversible inhibitor N-a-carbobenzyloxy-N-e-acryloyl-L-lysine (2-
(2-dansylaminoethoxy)ethoxy)ethanamide (NC9) (compound 9 in
[60]), which was initially used at 10-50 mM concentrations and
afterwards at 25 mM only. Toxicity of the inhibitor was tested by
analyzing MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tet-
razolium bromide) (Sigma) incorporation into viable cells. For all
osteoblast differentiation assays, cells were incubated with NC9 for
12 days in culture, in all other experiments cells were incubated for
6 days unless otherwise indicated. For TG substrate analysis, cells
were grown in the presence of 0.1 mM monodansyl cadaverine
(MDC) (Invitrogen, Ca, USA) for 6 days in culture, and then
prepared for IFM as described below.
In situ transglutaminase assay
To study the effect of NC9 on TG activity in situ, cells were grown
in DM for 6 days in culture, and then treated with 1 mM 5-
biotinamide pentylamine (bPA) (Pierce Biotechnology, Rockford, IL)
for 12 h before the termination of the experiment. Cells were then
prepared for immunofluorescence microscopy (as described below)
and stained using anti-biotin antibody (rabbit polyclonal antibody,
Rockland, PA, USA) and visualized as described below. Quantifi-
cation of immunofluorescence intensity was performed using
IMAGE-J software (version 1.37a, National Institutes of Health,
USA)wheretheintegrateddensityofpixels(sumofthegrayvaluesof
each pixel in determined area) of the given image was measured.
Picrosirius staining and collagen quantification
Collagen production by osteoblasts was assessed by quantifica-
tion of collagen using Picrosirius Red staining as previously
described [99]. Soluble calf skin collagen type I (Sigma) was used
for generating standard curves.
Mineralization and calcium assay
Mineral deposition into the formed collagenous extracellular
matrix was visualized by staining the cells at day 12 with 3% silver
nitrate (von Kossa staining). Calcium deposition was assessed by
measuring Ca
2+ levels from hydrochloric acid extracts of cell layers
using a calcium kit (Diagnostic Chemicals Limited, Oxford, CT).
Preparation of protein extracts, conditioned medium,
subcellular fractions and cell surface proteins
For proteinanalysis, total cell lysates were prepared by harvesting
the cell/matrix layer at the indicated time points using a mild
extraction buffer containing 10 mM Tris-HCl pH 7.4, 0.25%
sucrose, 0.2% IGPAL, and 1 mM PMSF prepared in phosphate-
buffered saline (PBS). Cells extracts were homogenized by
ultrasonication directly after extraction and centrifuged at 75006g
for 15 minutes at 4uC. The supernatant was collected and referred
to hereafter as total protein extract. Conditioned medium was
prepared by changing the cell culture medium to serum-free
medium 24 h prior to collection. Subcellular protein fractions
where prepared using ProteoExtract Subcellular Proteome Extrac-
tion Kit (S-PEK) (EMD Biosciences) following the manufacturer’s
instructions. Cytoplasmic (C), plasma membranous (Me), cytoskel-
etal and matrix (Ck/m) preparations were used for this study.
Proteins presented on the cell surface were isolated using a cell
surface protein isolation kit (Pierce Biotechnology, Rockford, IL)
following the manufacturer’s instructions. Deoxycholate (DOC)
soluble and insoluble material was prepared as described previously
in [100] in brief, cell layers were washed with serum free medium,
and lysed with DOC lysis buffer (2% deoxycholate, 20 mM Tris-
HCl pH 8.8, 2 mM PMSF, 2 mM EDTA, 2 mM iodoacetic acid,
and 2 mM N-ethylmaleimide). Samples were then centrifuged at
7500 g for 15 min at 10uC and the supernatant was collected and
labeled as DOC soluble material. The pellet (containing the DOC
insoluble material) was dissolved in DOC insoluble lysis buffer (2%
SDS 25 mM Tris-HCl pH 8.8, 2 mM PMSF, 2 mM EDTA,
2 mM iodoacetic acid, and 2 mM N-ethylmaleimide). Protein
concentrations of all preparations were determined with a
bichinchonic acid (BCA) protein assay kit (Pierce Biotechnology,
Rockford, IL).
Western blotting
For Western blot analysis, 10 mg of protein were dissolved in 5
X SDS loading buffer containing b-mercaptoethanol, and boiled
for 5 minutes at 100uC. If samples were run in nonreducing
condutioned no b-mercaptoethanol was included in sample buffer.
Proteins were separated on 10% SDS-polyacrylamide gels under
reducing conditions. Subsequently the proteins were transferred
onto PVDF membranes, which were blocked in 5% nonfat milk.
Membranes were then detected using primary antibodies against
the following antigens; COL I (rabbit polyclonal antibody,
Millipore), COL I C-terminal pro-peptide (LF-41, rabbit poly-
clonal antibody, courtesy of Dr. Larry W. Fisher, NIDCR), FN
(rabbit polyclonal antibody, Millipore), dansyl-group (rabbit
polyclonal antibody, Invitrogen), TG2 (mouse monoclonal anti-
body, CUB7402/TG100, Thermo scientific), mouse FXIIIA 675-
688 peptide sequence (polyclonal antibody, designed and gener-
ated by GenScript corporation, USA), synaptotagmin VII (goat
polyclonal antibody, Santa Cruz Biotechnology INC., CA, USA),
a-tubulin (mouse monoclonal, clone DM1A, Sigma), Glu-tubulin
(Rabbit polyclonal antibody, Millipore), Tyr-tubulin (Rabbit
polyclonal antibody, Millipore), vimentin (goat polyclonal anti-
body, Abcam), b-actin (rabbit polyclonal antibody, Sigma) or pan-
cadherin (rabbit polyclonal antibody, Abcam) for 2 h at room
temperature, followed by brief washing and incubation for 1 h
with horseradish peroxidase (HRP-) conjugated anti-mouse
(Amersham, Biosciences, Piscataway, NJ), anti-rabbit (Cell Signal-
ing, MA, USA) or anti-goat secondary antibody (Invitrogen, Ca,
USA) at room temperature. Reactions were visualized using an
ECL detection kit (Amersham Biosciences). Quantification of
bands was done with Quantity One software (v 4.5, Bio-Rad).
Immunofluorescence microscopy
Cells were grown for 6 days on Permanox 8 chamber slides (Lab-
Tek Chamber slides, Nalge Nunc International) as indicated above
and previously described (Al-Jallad et al., 2006). In short, on day 6
the growth medium was aspirated and the cell layers were rinsed
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formaldehyde in PBS. For visualization of intracellular proteins,
cells were permeabilized with 0.25% Triton X-100 (Sigma) in PBS,
whereas for visualization of cell surface and extracellular matrix
proteins, permeabilization was omitted. To reduce nonspecific
antibody binding, cells were blocked in 2% bovine serum albumin
(BSA, Sigma) in PBS for 30 minutes at room temperature. Slides
were then stained using antibodies against the following proteins;
COL I (rabbit and goat polyclonal antibodies, Millipore), FN
(mouse monoclonal antibody, Sigma), dansyl-group (rabbit poly-
clonal antibody, Invitrogen), TG2 (mouse monoclonal antibody,
CUB7402/TG100, Thermo scientific), mouse FXIIIA 675–688
peptide sequence (polyclonal antibody, designed and generated by
GenScript corporation, USA), synaptotagmin VII (goat polyclonal
antibody, Santa Cruz Biotechnology, Inc) and a-tubulin (mouse
monoclonal, clone DM1A, Sigma). Actin cytoskeleton was
visualized by Alexa Fluor 594 Phalloidin (Invitrogen) and nuclei
were visualized with DAPI (Invitrogen). All antibodies were diluted
in 0.1% BSA in PBS and cells were incubated with antibody
dilutions as required at room temperature for 2 h. Cells were
washed with 0.1% BSA in PBS and incubated with Alexa Fluor
secondary antibodies against mouse, rabbit, or goat primary
antibodies with wavelength excitations of 488 (green) or 568
(orange) (Invitrogen). Negative controls involved omission of
primary antibodies and secondary antibodies. In case of new anti-
mouse FXIIIA 675–688 antibody, also preimmune serum was used
as a negative control. For colocalization, controls included staining
for each primary antibody separately to exclude any cross reactivity
between the two antibodies used. Slides were mounted with Gold
anti-Fade medium (Invitrogen), dried overnight, and observed with
a Leica DM IL inverted fluorescent microscope or by with a Leica
DM 4000 B upright fluorescence microscope equipped with the
Volocity image acquisition software (PerkinElmer, Toronto, ON).
Black and white high-contrast images were generated from initial
color images using Adobe Photoshop; images were subjected to
brightness and contrast manipulation only.
Statistical analysis
Experimental error is expressed as standard error of the mean
(s.e.m.) of three independent experiments. Statistical significance
was assessed by applying Student’s T-test using Microsoft Excel
software. P values are as follows: *p.0.1, **p.0.001, ***p.0.001.
Supporting Information
Figure S1 Effect of control compound NC10 on osteo-
blast collagen deposition in osteoblast cultures. (A)
Structre of NC10. (B) Picrosirious staining of COL I in cultures
treated with either inhibitor NC9 or control NC10. COL I
remained at similar levels as in controls with NC10. (C) Western
blot analysis using anti-dansyl antibody. No dansyl group was
observed to be incorporated into any proteins in cultures grown in
the presence of NC10.
(TIF)
Figure S2 FXIIIA antibody (Ab676) validation. (A)(B)
Immunofluoresence and RT-PCR detection of FXIIIA in medium
only treated and differentiating MC3T3-E1 osteoblasts. Non-
differentiating cells express very low levels of FXIIIA and do not
show any cellular FXIIIA staining with rabbit polyclonal antibody
Ab676. (C) FXIIIA knockout osteoblasts were isolated from mouse
calvariae according to a previously reported methods [101] and
grown in culture for 10 days. Proteins were extracted and FXIIIA
was detected by Western blotting. Rabbit polyclonal antibody
Ab675 is shown to detect full length FXIIIA in wild type (WT) cells
but not in FXIIIA deficient osteoblasts.
(TIF)
Figure S3 Immunofluoresence staining of cytosolic
GAPDH and nuclear stain DAPI in nonpermeabilized
and permeabilized cells. Staining patters show that permea-
bilization allows visualization of cytosolic protein (GAPDH) where
as omission of this step block this staining. DAPI staining is visible
with both techniques.
(TIF)
Figure S4 Effect of NC9 on MTs in cells that do not
express FXIIIA. Tubulin staining in nonpermeabilized MC3T3-
E1 osteoblasts grown with medium only and in the presence and
absence of NC9. Figure S3 shows that these cells do not express
FXIIIA. Staining patterns show that patchy MT network on the
plasma membrane is not affected.
(TIF)
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